We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+55.66%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.22B
AUM Growth
+$309M
Cap. Flow
+$82.5M
Cap. Flow %
6.76%
Top 10 Hldgs %
72.94%
Holding
57
New
4
Increased
7
Reduced
9
Closed
10

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$148M
2
GERN icon
Geron
GERN
+$14.8M
3
TRML
Tourmaline Bio
TRML
+$11.8M
4
ENGN icon
enGene Therapeutics
ENGN
+$6.01M
5
PHVS icon
Pharvaris
PHVS
+$5.77M

Top Sells

Rank Stock Value
1
SVA
Sinovac Biotech, Ltd
SVA
+$38.2M
2
ACLX
Arcellx
ACLX
+$18.1M
3
VTYX
Ventyx Biosciences
VTYX
+$14.7M
4
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$13M
5
TARS icon
Tarsus Pharmaceuticals
TARS
+$7.98M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Consumer Staples 0%
3 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLNN icon
51
Clene
CLNN
$68.9M
– –
-132,267
Closed -$1.4M
FULC icon
52
Fulcrum Therapeutics
FULC
$283M
– –
-520,000
Closed -$2.31M
VTYX
53
DELISTED
Ventyx Biosciences
VTYX
– –
-422,075
Closed -$14.7M
ASLN
54
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
– –
-71,023
Closed -$1.07M
IMPL
55
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
– –
-2,884,789
Closed -$1.24M
AMRS
56
DELISTED
Amyris Inc.
AMRS
– –
-7,750,828
Closed -$465K
SVA
57
DELISTED
Sinovac Biotech, Ltd
SVA
– –
-5,900,000
Closed -$38.2M
1 2
3

Similar funds

FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
TIM
Tortoise Investment Management White Plains, New York $1.21B AUM 13.04% 1-Year Est. Return
CS
Central Securities New York $1.21B AUM 19.91% 1-Year Est. Return
KOC
Koss-Olinger Consulting Gainesville, Florida $1.19B AUM 15.91% 1-Year Est. Return

Vivo Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Vivo Capital held 57 positions worth $1.22B, up 34% from $913M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Vivo Capital deployed $82.5M of net new capital in Q4 2023, opening 4 new positions and adding to 7 existing holdings. Its largest new stake was Tourmaline Bio: 591,882 shares worth $15.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Consumer Staples and Materials.

On the sell side, the largest reduction was RayzeBio, Inc. Common Stock, an estimated $13M trimmed.

  • Vivo Capital's largest Q4 2023 buy was Tourmaline Bio: 591,882 shares worth $15.5M.
  • Vivo Capital added most to Soleno Therapeutics in Q4 2023, an estimated $148M increase.
  • Vivo Capital's biggest Q4 2023 reduction was RayzeBio, Inc. Common Stock, cutting an estimated $13M.
  • Vivo Capital fully exited Sinovac Biotech, Ltd in Q4 2023, selling an estimated $38.2M.
  • Vivo Capital's ten largest holdings make up 73% of its $1.22B portfolio in Q4 2023.
  • Vivo Capital opened 4 new positions and closed 10 in Q4 2023.
  • Vivo Capital's portfolio value rose 34% quarter-over-quarter to $1.22B.

Based on Vivo Capital's 13F filing for Q4 2023, filed 7 Feb 2024.